| Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo S Joshi, AR Singh, M Zulcic, L Bao, K Messer, T Ideker, J Dutkowski, ... PloS one 9 (4), e95893, 2014 | 128 | 2014 |
| A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis S Joshi, AR Singh, M Zulcic, DL Durden Molecular Cancer Research 12 (10), 1520-1531, 2014 | 125 | 2014 |
| Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis FH Andrews, AR Singh, S Joshi, CA Smith, GA Morales, JR Garlich, ... Proceedings of the National Academy of Sciences 114 (7), E1072-E1080, 2017 | 121 | 2017 |
| Vascular remodeling underlies rebleeding in hemophilic arthropathy V Bhat, M Olmer, S Joshi, DL Durden, TJ Cramer, RFW Barnes, ST Ball, ... American journal of hematology 90 (11), 1027-1035, 2015 | 99 | 2015 |
| Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system S Joshi, DL Durden Journal of oncology 2019 (1), 5245034, 2019 | 98 | 2019 |
| MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner S Joshi, AR Singh, DL Durden Journal of Biological Chemistry 289 (33), 22785-22797, 2014 | 96 | 2014 |
| DNA binding and topoisomerase II inhibitory activity of water-soluble ruthenium (II) and rhodium (III) complexes SK Singh, S Joshi, AR Singh, JK Saxena, DS Pandey Inorganic chemistry 46 (25), 10869-10876, 2007 | 85 | 2007 |
| Targeting the tumor microenvironment in neuroblastoma: recent advances and future directions S Joshi Cancers 12 (8), 2057, 2020 | 63 | 2020 |
| Single agent and synergistic activity of the “first-in-class” dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma AR Singh, S Joshi, AM Burgoyne, JK Sicklick, S Ikeda, Y Kono, JR Garlich, ... Molecular cancer therapeutics 15 (11), 2553-2562, 2016 | 59 | 2016 |
| Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication GR Campbell, RS Bruckman, SD Herns, S Joshi, DL Durden, SA Spector Journal of Biological Chemistry 293 (16), 5808-5820, 2018 | 57 | 2018 |
| Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors LLR Hartman, JR Crawford, MT Makale, M Milburn, S Joshi, AM Salazar, ... Journal of pediatric hematology/oncology 36 (6), 451-457, 2014 | 53 | 2014 |
| “Re-educating” tumor associated macrophages as a novel immunotherapy strategy for neuroblastoma KX Liu, S Joshi Frontiers in immunology 11, 1947, 2020 | 47 | 2020 |
| SF2523: Dual PI3K/BRD4 inhibitor blocks tumor immunosuppression and promotes adaptive immune responses in cancer S Joshi, AR Singh, KX Liu, TV Pham, M Zulcic, D Skola, HB Chun, ... Molecular cancer therapeutics 18 (6), 1036-1044, 2019 | 40 | 2019 |
| Molecular cloning and characterization of Plasmodium falciparum transketolase S Joshi, AR Singh, A Kumar, PC Misra, MI Siddiqi, JK Saxena Molecular and biochemical parasitology 160 (1), 32-41, 2008 | 39 | 2008 |
| Vascular permeability and remodelling coincide with inflammatory and reparative processes after joint bleeding in factor VIII-deficient mice EJ Cooke, JY Zhou, T Wyseure, S Joshi, V Bhat, DL Durden, LO Mosnier, ... Thrombosis and haemostasis 118 (06), 1036-1047, 2018 | 36 | 2018 |
| Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126 A Erdreich-Epstein, AR Singh, S Joshi, FM Vega, P Guo, J Xu, S Groshen, ... Oncotarget 8 (32), 52193, 2017 | 35 | 2017 |
| PI-3K inhibitors preferentially target CD15+ cancer stem cell population in SHH driven medulloblastoma AR Singh, S Joshi, M Zulcic, M Alcaraz, JR Garlich, GA Morales, YJ Cho, ... PloS one 11 (3), e0150836, 2016 | 35 | 2016 |
| Design and performance characteristics of a solar box cooker with phase change material: A feasibility study for Uttarakhand region, India A Kumar, A Saxena, SD Pandey, SK Joshi Applied Thermal Engineering 208, 118196, 2022 | 32 | 2022 |
| Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression S Joshi, KX Liu, M Zulcic, AR Singh, D Skola, CK Glass, PD Sanders, ... Molecular cancer therapeutics 19 (3), 755-764, 2020 | 31 | 2020 |
| Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype S Joshi, AR Singh, SS Wong, M Zulcic, M Jiang, A Pardo, M Selman, ... PloS one 12 (8), e0182851, 2017 | 30 | 2017 |
